Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
Abstract The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical, laboratory and echocardiographic parameters and outcomes in a real-world population with heart failure with reduced ejection fraction (HFrEF). This was a prospective observational study enrolling pa...
Guardado en:
Autores principales: | Maria Vincenza Polito, Angelo Silverio, Antonella Rispoli, Gennaro Vitulano, Federica D’ Auria, Elena De Angelis, Francesco Loria, Alberto Gigantino, Domenico Bonadies, Rodolfo Citro, Albino Carrizzo, Gennaro Galasso, Guido Iaccarino, Carmine Vecchione, Michele Ciccarelli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c4eb79d743ba47cb96ae9674c35a7a14 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sacubitril/valsartan in real-life clinical practice
por: Yüksel Çavuşoğlu
Publicado: (2021) -
Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats
por: Jiao Ai, et al.
Publicado: (2021) -
Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hui-Ling Hsieh, et al.
Publicado: (2021) -
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
por: Cuthbert JJ, et al.
Publicado: (2020) -
Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts
por: Xiaofei Li, et al.
Publicado: (2021)